BPC-157

We evaluated 13 human studies on BPC-157, including one meta-analysis or systematic review; there are no controlled human studies yet. As of 3 October 2026.

This page as PDF · Summary

1. What Is BPC-157? Occurrence, Origin and Forms

BPC-157 (Body Protection Compound 157) is a laboratory-made peptide of 15 amino acids. Its sequence matches a section of a protein found in human gastric juice; the peptide itself does not occur in the body in this form.

BPC-157 does not occur in food. It is produced exclusively by chemical synthesis.

It is produced by peptide synthesis. It is mostly offered as a powder to be dissolved for injection and in capsules; it is not approved as a medicine. Most research comes from animal studies.

Forms and Preparations Studied

• Injection under the skin, into the muscle or into the joint
• Oral capsule or solution
• Combination products with BPC-157 – the other ingredients are named in each case

Not covered on this page:

• Other peptides such as TB-500 (thymosin beta-4) when BPC-157 is not included

2. What Does BPC-157 Do? Results by Area

How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.

3. What the Studies Show in Detail

BPC-157, Tendons, Ligaments and Muscles: Human Studies

For tendons, ligaments and muscles, no controlled studies in humans are available; the statements are based on reviews that evaluate almost only animal studies. In a systematic review, muscle, tendon, ligament and bone injuries healed better under BPC-157 in animal models 1. A review also describes better regeneration in tendons and myotendinous junctions, predominantly preclinical 8. Reliable statements about effects in humans cannot be derived from this.

BPC-157, Joints and Pain: Human Studies

For joints and pain, no controlled studies in humans are available, only small case series and reviews. In a case series without a control group, knee pain improved after injection into the joint in most patients 4. A review counts only three small pilot studies in humans and considers larger studies with a control group necessary 8. Reliable statements are not possible, because control groups are lacking and the case series are small.

BPC-157, Stomach and Gut: Human Studies

For the stomach and intestines, no controlled studies in humans are available; only review articles exist. One review article describes healing effects in the gastrointestinal tract without naming results in humans in detail 10. Another review article describes BPC-157 in clinical studies in inflammatory bowel diseases as safe, but does not name any results on efficacy 11. The peptide was studied as an injection as well as a capsule or solution; the overall strength of evidence is unclear because controlled comparisons in humans are lacking.

BPC-157, Blood Vessels and Wound Healing: Human Studies

For blood vessels and wound healing in humans, no controlled studies on BPC-157 are available. One review article reports better angiogenesis and endothelial repair, but relies predominantly on animal and laboratory models 8. Another review article describes effects on wound and fistula healing and on blood vessels without naming results in humans in detail 10. BPC-157 was studied as a synthetic peptide as well as intake as a capsule or solution; robust evidence for a benefit in humans is lacking.

BPC-157: Further Outcomes in Studies

For this area, no controlled studies in humans are available. According to a systematic review, BPC-157 increased the formation of growth hormone receptors in animal and laboratory studies and promoted signaling pathways of new blood vessel formation 1. The same review describes fewer inflammatory messengers, also from animal and laboratory studies 1. Proof of efficacy in humans remains open because the clinical observations are uncontrolled and the remaining studies are predominantly preclinical or narrative.

4. How Is BPC-157 Dosed? Preparation, Dose and Duration in Studies

The studies and reviews investigated BPC-157 as a synthetic peptide that was injected under the skin, into the muscle or into the joint. Individual papers also consider intake as a capsule or solution. In a case series, BPC-157 was also injected into the joint together with thymosin beta-4 (TB4) 4.

5. Is BPC-157 Safe? Side Effects in Studies

Two review articles report that BPC-157 showed no side effects in clinical studies 1011; a systematic review, by contrast, found no clinical safety data and considers side effects possible due to unregulated manufacturing and impurities 1.

6. What Remains Open: Limits of the Evidence

• No controlled studies in humans are available; all statements about effects are based on uncontrolled observations, case series and reviews.
• Many findings come from animal and laboratory models and cannot be directly transferred to humans.
• The clinical observations include very small case numbers without a control group.
• There are hardly any data on long-term tolerability and interactions in humans.
• If BPC-157 is combined with other peptides, effects cannot be attributed to BPC-157 alone.

7. Bottom Line: What Is Established About BPC-157

BPC-157 is a synthetic peptide made of 15 amino acids; its sequence corresponds to a section of a protein from human gastric juice. Regarding tendons, ligaments and muscles, joints and pain, as well as further measures, reviews and case series report positive observations, but without controlled comparisons in humans 18. Regarding stomach, intestine, blood vessels and wound healing, the findings come predominantly from animal experiments; on effectiveness in humans, the reviews report no results 81011.

The strength of evidence is consistently limited: there are no controlled studies in humans, the clinical observations are small and uncontrolled, and part of the data comes from preclinical models. Reliable statements about benefits and risks in humans cannot be derived from this.